Project - Benchmarking of biopharmaceutical science and technology in Canada
Client - Industry Canada (IC) - Life Science Brach (LSB)
Description - The Life Sciences Branch of Industry Canada commissioned Science-Metrix to benchmark Canadian science and technology (S&T) performance in the field of biopharmaceutics based on scientometrics and technometrics. The LSB plays a central role in developing policy and strategy for Canadian biopharmaceutics. This planning process is based on future and unfulfilled needs and aims to identify emergent science and technology which has or will have significant economic and social impacts for Canada.
The report presents a quantitative analysis (bibliometrics) of the Canadian biopharmaceutics industry, based on data from the Medline database of biomedical scientific publications and the United States Patents and Trademark Office (USPTO) database. The report provides performance comparisons both at the international level and within Canada, in the university, governmental and private sectors. The study also includes a detailed analysis of the performance of therapeutic and technological clusters. Great efforts were made to map these clusters in such a way as to identify key players and characterize the industry’s dynamics. Lastly, the report describes the evolution of the field on the international and national (provincial, metropolitan and institutional) levels.
A combined analysis of the specialization index and the quality of scientific publications identified Canada’s strengths and weaknesses in biopharmaceutics. Canada is a leading competitor in research on diabetes (antibodies technology applications, genomics and biophotonics), respiratory therapy (mimetics, regenerative medicine) and the use of multiple technological platforms linked to the development of hormones and hormonal control (regenerative medicine, antibodies, genomics, mimetics and nanotechnologies). However, Canada has weaknesses in the uses of mimetics for vaccines, genomics for dermatologic therapies and nanotechnologies for cancer treatment.
The project provided robust and unique indicators on the dynamics of science and innovation in biopharmaceutics and will be used in the development of a strategic plan for industry and academic and governmental research.
Archambault É., Bertrand F. and Côté G. 2003.
Benchmarking of Canadian Biopharmaceutical Science and Technology. Prepared for Industry Canada's Life Science Branch (LSB) by Science-Metrix, 56 pages.
[PDF] |
